newsfilter
← Earnings
Earnings Releases·

Structure Therapeutics — Third Quarter 2026 Earnings Summary

  • Cash and short-term investments decreased to $1.2 billion as of September 30, 2026, from $1.3 billion in June 2026, while net loss widened to $144.8 million for the quarter compared to $65.7 million in the prior year period.
  • The company expects its current cash position to fund operations and key clinical milestones through the end of 2028, with top-line data for Phase 3 aleniglipron trials (ACCOMPLISH-1 and ACCOMPLISH-2) anticipated in the second half of 2028.
  • Aleniglipron Phase 3 enrollment initiated in August 2026, and September 2026 data from the 72-week ACCESS extension showed up to 16.2% mean body weight reduction in the highest dose group with no observed plateau.
  • Additional clinical milestones include expected MAD trial data for ACCG-2671 in H1 2027, initiation of a Phase 1 trial for ACCG-3535 in Q4 2026, and further aleniglipron data from supplementary studies in Q4 2026.
  • Total operating expenses for the nine months ended September 30, 2026, rose to $364.3 million from $200.5 million in the same period of 2025, reflecting expanded infrastructure and increased employee expenses.
Company
STRUCTURE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology